Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
2023 Nice Insight Reports
Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking
Monoclonal Antibody & Recombinant Protein: 2023 Market Analysis, CDMO Pricing and Benchmarking
mRNA Vaccines & Therapeutics: 2023 Market Analysis, CDMO Pricing and Benchmarking
Sterile Drug Product: 2023 Market Analysis, CDMO Pricing and Benchmarking
Active Pharmaceutical Ingredients: 2023 Market Analysis, CDMO Pricing and Benchmarking
Antibody Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking
Contract Research Organizations: 2023 Market Analysis, Pricing and Benchmarking
Oral Solid Dosage: 2023 Market Analysis, CDMO Pricing and Benchmarking
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
COVID-19
251 Articles Available
0
11
Can't find what you're looking for? Try our
advanced search
.
Recombinant Proteins
The Expanding Role for Recombinant Proteins in Research
PAO-11-22-PATV-01
Mental Health
Mental Health During a Global Pandemic
PAO-06-022--NI-03
COVID-19 Breathalyzer Diagnostic
Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples
PR-M04-22-09
COVID-19 Vaccines
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
PAO-03-022-NI-05
Remote Auditing
Will Remote Pharma GMP Auditing Continue Post-COVID?
PAO-02-022-CL-21
Antibody Therapeutics
Developing New Antibody Therapeutics for COVID-19 and Beyond
PAO-01-22-CL-01
COVID-19 Vaccines
The Global Immunization Disparity
PAO-02-022-CL-04
COVID-19 Prevention
AstraZeneca to Supply Canada with 100,000 Doses of Evusheld, a Long-Acting Antibody Combination for the Prevention of COVID-19
PR-M02-22-21
COVID-19 Antiviral
Model Medicines' Oral Anti-COVID-19 Drug Candidate MDL-001 Found to Significantly Reduce Viral Load in Lungs; Accepted into NIH's Antiviral Program for Pandemics (APP)
PR-M02-22-05
COVID-19 Vaccine
FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine
PR-M02-22-01
COVID-19 Research
MU Study Identifies Mutations Specific to Omicron Variant
PR-M01-22-17
Data Connectivity
Discussing the Advancements in Oncology
PATV-12-21-01
Immunotherapy
Immune Biosolutions Reports That Its Lead Immunotherapy Product IBIO123 Neutralizes 100% of the SARS-CoV-2 Variants of Concern (VOCs), Including Omicron
PR-M01-22-06
Thermal Packaging
With Omicron Variant on the Rise, Thermal Custom Packaging (TCP) is Providing Secure Transportation of COVID Vaccine
PR-M01-22-02
Cell Therapy
Accelerating the Development of a Novel Cell Therapy for COVID-19–Associated Lung Fibrosis
PAO-09-21-CL-13
COVID19 Nasal Spray
pHOXBIO Announces Breakthrough Clinical Trial Results Concluding Prophylactic Nasal Spray Prevents Infection from SARS-CoV-2
PR-M09-21-07
COVID-19 Nasal Spray
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
PR-M07-21-05
COVID-19 Vaccine
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
PR-M06-21-028
COVID-19 Testing
Roche Obtains CE Mark for the SARS-CoV-2 Antigen Self Test Nasal Allowing for Rapid Self Testing of COVID-19 At Home
PR-M06-21-027
Partnership
Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
PR-M06-21-024
COVID-19
Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities
PR-M06-21-020
Genetic Vaccines
Working to Overcome Analytical Challenges Posed by Genetic Vaccines
PAO-06-21-NI-01
COVID-19 Treatment
Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19
PR-M06-21-003
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
PR-M05-21-016
«
0
11
»
